N. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced the first national contract signed for ABLAVAR® with Amerinet, Inc., a leading national healthcare group purchasing organization. ABLAVAR® (gadofosveset trisodium), is a unique, injectable MRA blood pool imaging agent indicated to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease (PVD). The agreement, effective May 1, 2010, makes ABLAVAR® available nationally to all Amerinet members and was awarded based on the fact that ABLAVAR® is the first and only FDA approved blood pool contrast agent for use with an MRA indication. Amerinet has more than 2,500 acute care hospitals and 25,000 alternate care members in its network of healthcare providers.
